Under the Paperwork Reduction Act of 1995, no persons are require

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10770098				
Filing Date		2004-02-02				
First Named Inventor	Daniel J. Miller					
Art Unit		2154				
Examiner Name						
Attorney Docket Number		MS1-0631USC2				

	U.S.PATENTS Remove							
Examiner Cite Initial* No		Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6038425		2000-03-14	Jeffrey			
	2	6356701		2002-03-12	Tanizawa, et al.			
	3	6519540		2003-02-11	Salandro			
	4	6675386		2004-01-06	Hendricks, et al.			
	5	6774919		2004-08-10	Miller, et al.			
	6	6882891		2005-04-19	Rudolph			
	7	6912717		2005-06-28	Miller, et al.			
	8	6954581		2005-10-11	Miller, et al.			
If you wis	h to ac	dd additional U.S. Pate	nt citatio	n information p	lease click the Add button.	Add		

	Application Number		10770098	
NEODIATION DIOCI COURT	Filing Date		2004-02-02	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor	Danie	el J. Miller	
	Art Unit		2154	
·,	Examiner Name			
	Attorney Docket Number		MS1-0631USC2	

Name of Patentee or Applicant

of cited Document

Kind Publication

Code¹ Date

Examiner Cite

Initial* No.

Publication Number

Pages, Columns, Lines where

Figures Appear

Relevant Passages or Relevant

	1								
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add FOREIGN PATENT DOCUMENTS Remove								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

Examiner Signature Date Considered Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at www.USPTO.GDQ or MPEP 901.04. 2 Enter office that sessed the document, by the two letter code (WIPO).

Standard ST.3. Fig. Japanese patent documents, the indication of the year of the region of the Empoor must precede the serial number of the patent document. A fixed of occurrent by the perporate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE							
	Filing Date		2004-02-02				
	First Named Inventor Danie		el J. Miller				
	(Not for submission under 37 CFR 1.99)	Art Unit		2154			
(Not for Submission under 67 of it 1.55)	Examiner Name						
		Attorney Docket Number		MS1-0631USC2			

10770098

Application Number

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to stee! hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggesterior for reducing this burder, should be sent the folder information Officer U.S. Pattern and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2215-1450, DO NOT SERVI TIME ADDRESS. SEMP TO: Commissioner for Pattern S.P.O. Box 1450, Alexandria,

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.